BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19795574)

  • 1. Update: chronic myelogenous leukemia clinical practice guidelines.
    O'Brien SM; Kantarjian H; Radich J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S29-40. PubMed ID: 19795574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
    Simon W; Segel GB; Lichtman MA
    Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelogenous leukemia clinical practice guidelines in oncology.
    O'Brien S;
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S14-28. PubMed ID: 19795573
    [No Abstract]   [Full Text] [Related]  

  • 4. [Stem cell transplantation in the imatinib era].
    Masszi T
    Orv Hetil; 2005 May; 146(18 Suppl 1):900-4. PubMed ID: 15921302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An advance in the treatment of CML].
    Ohnishi K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2185-90. PubMed ID: 18079618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Maziarz RT
    Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Kujawski LA; Talpaz M
    Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and epidemiologic burden of chronic myelogenous leukemia.
    Redaelli A; Bell C; Casagrande J; Stephens J; Botteman M; Laskin B; Pashos C
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):85-96. PubMed ID: 14748660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
    Maziarz RT; Mauro MJ
    Bone Marrow Transplant; 2003 Sep; 32(5):459-69. PubMed ID: 12942091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
    Mauro MJ; Maziarz RT
    Mayo Clin Proc; 2006 Mar; 81(3):404-16. PubMed ID: 16529146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [EBM in the treatment of CML].
    Ohnishi K
    Rinsho Ketsueki; 2005 Jun; 46(6):410-7. PubMed ID: 16447722
    [No Abstract]   [Full Text] [Related]  

  • 15. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
    Weisser M; Schmid C; Schoch C; Hiddemann W; Kolb HJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1017-8. PubMed ID: 16184176
    [No Abstract]   [Full Text] [Related]  

  • 16. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
    Minami Y; Naoe T
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myelogenous leukemia. Clinical practice guidelines in oncology.
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw; 2003 Oct; 1(4):482-500. PubMed ID: 19774740
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
    Ruiz-Argüelles GJ; Tarin-Arzaga LC; Gonzalez-Carrillo ML; Gutierrez-Riveroll KI; Rangel-Malo R; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Gómez-Almaguer D; Giralt S
    Bone Marrow Transplant; 2008 Jul; 42(1):23-8. PubMed ID: 18612313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
    Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
    Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.
    Majhail NS; Schiffer CA; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):789-91. PubMed ID: 16785069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.